How to access family office capital as a life scie...
Family Offices are, by design, a much more private group than other other i...
Read MoreThe headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.
Remember:
Get our executive insight into your inbox
Written By
Ewa Campbell
12 July 2016
Family Offices are, by design, a much more private group than other other i...
Read MoreBiotech and Money are pleased to announce the release of the latest Drugs &...
Read MoreLeaving the EU would have enormous implications for biotech and life scienc...
Read MoreIn this article, Professor Lord Darzi of Denham, director of the Institute ...
Read MoreIf the UK votes to exit the European Union (Brexit) following the referendu...
Read MoreWith the UK's referendum on whether Britain should leave the European Union...
Read MoreAt the Inv€$table CEO Pitch Breakfast hosted by K&L Gates on Tuesday 24th M...
Read MoreLeaders from across scientific disciplines tell MPs leaving EU would relega...
Read MoreCaroline Barelle, CEO of Elasmogen, took the time to grant us an interview ...
Read MoreIn this article,Claire Skentelberylooks at the potential consequences for t...
Read MoreThe UK faces one of its biggest economic and political decisions in recent ...
Read MoreOn the evening of the 31st March, 'Biotechs and the City Spring' was the la...
Read MoreThe Drugs & Dealers Blog provides genuine thought leadership, exclusive executive insight and market intelligence on the life science and healthcare investment sector.
In partnership with Medius Associates
Medius' monthly review of the top deals by value in the healthcare sector
Connecting Europe's Life Science corporates with capital.
Biotech and Money is the influential community of senior life science decision makers
© 2016 All Rights Reserved By Biotech and Money
Add Your Response